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Selectin-mediated activation of endothelial cells induces
expression of CCL5 and promotes metastasis through
recruitment of monocytes
Abstract
Hematogenous metastasis is promoted by interactions of tumor cells with leukocytes, platelets and the
endothelium in the local intravascular microenvironment. Here we show that the activation of the
microvascular endothelium results in recruitment of monocytes to metastatic tumor cells and promotes
the establishment of the metastatic microenvironment. This inflammatory-like endothelial response was
observed in microvascular endothelial cells only. Microarray analysis of microvascular endothelial cells
co-cultured with tumor cells in the presence of leukocytes and platelets revealed a specific gene
expression profile. Selectin-mediated interactions of tumor cells with platelets and leukocytes activated
endothelial cells and induced production of CCL5. Inhibition of CCL5-dependent monocyte recruitment
during the early phase of metastasis by a CCL5 receptor antagonist strongly reduced tumor cell survival
and attenuated metastasis. Collectively, these findings demonstrate that the endothelial expression of
CCL5 contributes to the formation of a permissive metastatic microenvironment.
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VASCULAR BIOLOGY
Selectin-mediated activation of endothelial cells induces expression of CCL5 and
promotes metastasis through recruitment of monocytes
Heinz La¨ubli,1,2 Katharina-Susanne Spanaus,3 and Lubor Borsig1,2
1Institute of Physiology, University of Zu¨rich, Zu¨rich; 2Zu¨rich Center for Integrative Human Physiology, Zu¨rich; and 3Institute of Clinical Chemistry, University
Hospital Zu¨rich, Zu¨rich, Switzerland
Hematogenous metastasis is promoted by
interactions of tumor cells with leukocytes,
platelets, and the endothelium in the local
intravascular microenvironment. Here we
show that the activation of the microvascu-
lar endothelium results in recruitment of
monocytes to metastatic tumor cells and
promotes the establishment of the meta-
static microenvironment. This inflammatory-
like endothelial response was observed in
microvascular endothelial cells only. Mi-
croarray analysis of microvascular endothe-
lial cells cocultured with tumor cells in the
presence of leukocytes and platelets re-
vealed a specific gene expression profile.
Selectin-mediated interactions of tumor cells
withplateletsand leukocytesactivatedendo-
thelial cells and induced production of C-C
chemokine ligand 5 (CCL5). Inhibition of
CCL5-dependent monocyte recruitment dur-
ing the early phase of metastasis by a CCL5
receptor antagonist strongly reduced tumor
cell survival and attenuated metastasis. Col-
lectively, these findings demonstrate that
the endothelial expression of CCL5 contrib-
utes to the formation of a permissive meta-
static microenvironment. (Blood. 2009;114:
4583-4591)
Introduction
Metastasis remains the major cause for cancer-related death. Hematoge-
nous metastasis comprises multiple steps including tumor cell dissemi-
nation through the circulation, arrest in the microvasculature, and
ultimately colonization of distant organs.1,2 The known inefficiency of
the metastatic process implies that tumor cells are very limited in ability
to colonize and to grow in healthy tissues of distant organs.3 Thus, tumor
cells survive and proliferate at distant sites only within a favorable
microenvironment.3 Cell-cell interactions among tumor cells, platelets,
leukocytes, and endothelial cells were shown to contribute to the
enhanced tumor cell survival and to the facilitation of hematogenous
metastasis.3,4 Platelet association with intravascular tumor cells en-
hances hematogenous dissemination and protects tumor cells from
immune-mediated clearance.5,6 Activated platelets release cytokines and
present surface molecules, which are able to activate endothelial cells.7
Several cell adhesion molecules including glycoprotein IIb/IIIa integrin
and P-selectin are known to mediate platelet–tumor cell interactions and
facilitate metastasis.8,9 In addition, activated platelets are commonly
observed in the circulation of cancer patients.10
Although the contribution of leukocytes to the formation of primary
tumors is well recognized, mechanisms by which leukocytes govern the
process of metastasis remains poorly understood.11,12 Depending on the
microenvironmental signals, leukocytes can either exert antitumoral
activity or promote cancer progression.12 Tumor-associated myeloid
cells including polymorphonuclear leukocytes (PMNs), monocytes, as
well as differentiated macrophages were shown to facilitate immunosup-
pression, angiogenesis, tumor cell survival, and invasion and thereby
contribute to metastatic dissemination.11,12 Previously, we showed that
the absence of L-selectin results in an attenuation of tumor cell survival
and metastasis, implicating leukocytes in the colonization process.13,14
Activation of the endothelium is observed both in advanced cancer
patients and within the microenvironment of experimentally metastasiz-
ing tumor cells.15-17 Activated microvascular endothelial cells increase
the expression of cell adhesion molecules and the production of
chemokines, which leads to a recruitment of leukocytes, neutrophils,
and monocytes.18 The activated state of endothelial cells is reflected in
increased levels of soluble endothelial cell adhesion molecules, for
example, E-selectin and vascular cell adhesion molecule 1 (VCAM-1),
as found in the serum of colorectal cancer patients.17 In a mouse model
of liver metastasis, sinusoidal microvascular endothelial cells were
activated upon interaction of colorectal tumor cells with resident
Kupffer cells.15 Inhibition of endothelial activation was shown to
attenuate metastasis in several mouse models.4,16,19 By contrast, experi-
mental activation of the endothelium by the administration of cytokines
prior to the inoculation of tumor cells led to enhanced metastasis.20
Although the local importance of the endothelium in metastasis is
increasingly accepted, its function in the creation of the metastatic
microenvironment remains poorly understood. The present study was
designed to analyze the function of the endothelium during the initial
steps of metastasis. Here we report that interactions of tumor cells with
platelets and leukocytes activate microvascular endothelial cells, result-
ing in up-regulation of endothelial C-C chemokine ligand 5 (CCL5)
production and promotion of metastasis.
Methods
Cell culture
Human colorectal cancer cells LS180 and Caco-2 were grown in Dulbecco
modified Eagle medium with 10% fetal calf serum (Invitrogen). HT-29 and
Colo205 cells were grown in McCoy and RPMI 1640 medium containing
10% fetal calf serum (Invitrogen), respectively. MC-38GFP murine carci-
noma cells were grown as described previously.13 Human lung microvascu-
lar endothelial cells (HMVECs) and human umbilical vein endothelial cells
(HUVECs) were cultured on fibronectin-coated plates in endothelial cell
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growth medium–2 microvascular (EGM-2MV) or EGM-2 medium, respec-
tively (Lonza).
Isolation of platelets and leukocytes
Human platelets were isolated as described previously.21 Briefly, 50 mL
citrated blood from healthy volunteers was centrifuged at 200g. Platelets
collected in the upper phase were washed in piperazine-1,4bis(2-
ethanesulfonic acid (PIPES) buffered saline (pH 6.8). Peripheral blood
mononuclear cells were separated from PMNs and red blood cells on a
Ficoll gradient (GE Health Services). PMNs were purified by dextran
sedimentation, followed by lysis of red blood cells with PharmLyse (BD
Biosciences). Monocytes were isolated from peripheral blood mononuclear
cells using the monocyte isolation kit II (Miltenyi Biotec). The purity of
blood elements reached more than 95% in all experiments as confirmed by
Wright-Giemsa staining and flow cytometry.
Coculture and magnetic separation of endothelial cells
Adherent, quiescent HMVECs or HUVECs were cocultured with tumor cells
(2 105 cells per milliliter), PMNs, monocytes, and platelets in EGM-2MV or
EGM-2 cell medium, respectively. Leukocytes and platelets were added at
similar ratios as found in the human blood (4 106 PMNs, 4 105 monocytes,
and 150 106 platelets per milliliter). After 8 hours of coculture, adherent cells
were detached and incubated with biotinylated anti-CD11b and anti–epithelial
cell adhesion molecule (EpCAM) monoclonal antibodies (BD Biosciences and
Neomarkers), followed by magnetic cell depletion using anti–biotin-beads
(Miltenyi Biotec). The purity of blood elements reached more than 95% in all
experiments as confirmed by Wright-Giemsa staining and flow cytometry
(supplemental Figure 1, available on the Blood website; see the Supplemental
Materials link at the top of the online article).
RNA isolation and microarray analysis
Total endothelial RNA was isolated using Tri-Reagent (Sigma-Aldrich).
Biotinylated cRNA was hybridized to Affymetrix Human Genome U133
Plus 2.0 oligonucleotide microarrays and labeled according to the manufac-
turer’s protocol (Affymetrix). Microarrays were scanned with the Af-
fymetrix Scanner 3000 and intensities were MAS 5.0 normalized (Af-
fymetrix). Determination of differential expression was performed with the
GeneSpring software (Agilent). All microarray analysis has been deposited
into the GEO public database under accession number GSE18113.22
Quantitative RT-PCR
After the removal of genomic DNA by DNAse digestion (Promega) single-
stranded cDNA (QIAGEN) was prepared from total RNA. Primers for human
CCL5, matrix metalloproteinase-1 (MMP1), MMP10, regulator of G-protein
signaling 4 (RGS-4), versican, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), EpCAM, C-C chemokine receptor type 5 (CCR5), and murine CCL5
and GAPDH are listed in supplemental Table 1. Quantitative polymerase chain
reaction (PCR) was performed in a MX-300P thermocycler (Stratagene) using a
SYBR Green kit (Sigma-Aldrich) and relative changes were quantified.
Detection of CCL5 secretion
Endothelial cells were cocultured in different conditions for 8 hours.
Washed, adherent cells were incubated in freshly added medium for another
12 hours. Protein concentration of CCL5 in the supernatant was analyzed
with a cytometric bead array (CBA; BD Biosciences).
Detection of CCL5 in vivo
Lung cryosections from mice injected with MC-38GFPcells were incubated with
an antimurine CCL5 antibody (R&D Systems), and anti–CD31-biotin–
conjugated antibody (BD Biosciences). CCL5 staining was detected with
donkey-anti–goat Ab conjugated with Alexa 568 (Invitrogen), and CD31
endothelial cells were detected by streptavidin-Alexa 660 (Invitrogen). The
presence of CCL5 in tissues was analyzed with a confocal microscope (SP5;
Leica) and images were quantified with the Imaris software (Bitplane).
Endothelial cell activation
HMVECs or HUVECs were cocultured in different conditions for 8 hours. In
some experiments, 10g/mL of a P-selectin blocking antibody (Syngenta) was
added to the coculture or tumor cells were treated with O-sialoglycoproteinase
(OSGPase; Cedarlane). After coculture, cells were detached with 2 mM ethyl-
enediaminetetraacetic acid/phosphate-buffered saline (PBS) and incubated with
an anti-CD105 (R&D Systems) and anti–E-selectin (BD Biosciences) antibodies,
followed by flow cytometry (FACSCanto; BD Biosciences).
Chemotaxis and adhesion assays
HMVEC layers were washed twice after 12 hours of coculture. Transwell
inserts (8 M; BD Biosciences) containing 3  105 PKH2-labeled (Sigma-
Aldrich) human monocytes were placed over the cocultured, washed
HMVEC layers. Migrated PKH2-positive cells were counted in the lower
chamber after 8 hours. In some experiments, 1 g/mL of a CCL5 function-
blocking antibody (2D5; BD Biosciences) or the corresponding isotype
control (MOPC-21; BD Biosciences) was added. In others, Met-RANTES
was added (2 g/mL).23
Adhesion of PKH2-labeled monocytes (105) to the activated cocultured
HMVECs was analyzed after 2 hours of incubation.
Nuclear translocation of p65
HMVECs and HUVECs were cocultured in different conditions. Cells
were stained with anti-p65 and anti–CD31-fluorescein isothiocyanate
(BD Biosciences) monoclonal antibodies in PBS containing 1% bovine
serum albumin and 0.1% Triton X-100. Staining of p65 was detected
with goat-anti–mouse Ab conjugated with Alexa 568 (Invitrogen).
Slides were mounted with Prolong and analyzed by confocal microscopy
(SP5; Leica; magnification 63/1.30 NA oil objective). Measurements
were normalized to the background signal of p65 nuclear localization in
quiescent endothelial cells.
Experimental metastasis model
C57BL/6J mice were intravenously injected with murine MC-38GFP
cells (3  105) and metastasis was evaluated by green fluorescent protein
(GFP) measurement in lung homogenates after 21 days.13 Mice received
10 g Met-RANTES intraperitoneally 6 hours before and 6, 18, 30, and
42 hours after the tumor cell injection.
Human LS180 cells (4.5  105) were intravenously injected in NMRI
athymic mice that were treated with Met-RANTES during the first
48 hours. After 5 weeks, mice were killed and the extent of metastasis was
determined by a quantitative reverse-transcription (RT)–PCR for detection
of human-specific EpCAM transcripts isolated from murine lungs. Meta-
static nodules were counted in lung sections stained with hematoxylin and
eosin (Leica SP5; magnification 40/0.75 NA air objective). All animal
protocols were approved by the Zu¨rich Kantonal committee.
Analysis of leukocyte–tumor cell association
Lung sections prepared from mice intravenously injected with MC-38GFP
cells were stained with a F4/80 monoclonal antibody (AbD) detecting
macrophages/monocytes. F4/80 staining was visualized by the secondary
goat-anti–rat Ab conjugated with Alexa 568 (Invitrogen).
Statistics
Statistical analysis was performed with the GraphPad Prism software (Ver-
sion 4.0) or Genespring GX software (Version 7.3; Agilent). All data are
presented as mean plus or minus SEM and were analyzed by analysis of variance
(ANOVA) with the posthoc Bonferonni multiple comparison test, unless
specified differently.
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Results
Tumor cells activate microvascular endothelial cells only in the
presence of leukocytes and platelets
The assessment of the temporal and spatial molecular interactions
causing the endothelial activation during metastatic initiation is
technically difficult in vivo. We therefore developed an in vitro
coculture system mimicking the hematogenous metastatic micro-
environment. Human tumor cells, LS180 and Colo205, were cul-
tured on monolayers of human microvascular endothelial cells
(HMVECs) and the activation status of the endothelial cells was
determined by E-selectin detection. Cell surface expression of
E-selectin is associated with endothelial activation.15,18 Tumor
cells alone did not induce expression of E-selectin on HMVECs
(Figure 1A-B). We then hypothesized that leukocytes and platelets
can contribute to the tumor cell–induced endothelial cell activation
observed in vivo.4,15,16 We previously described the recruitment of
innate immune cells, PMNs and monocytes, to metastasizing
tumor cells.14 Therefore PMNs, monocytes, and platelets were
added to the coculture of tumor cells on HMVECs. A strong
induction of E-selectin expression on HMVECs was observed both
with LS180 and Colo205 cells in this coculture condition (Figure
1A-B). Similarly, an enhanced expression of VCAM-1, an alter-
nate activation marker of endothelial cells, was detected on
HMVECs (supplemental Figure 2). In contrast, coculture of tumor
cells individually with either platelets, PMNs, or monocytes
caused no or minimal expression of E-selectin, further supporting
the requirement of several blood elements for endothelial activa-
tion (supplemental Figure 2). Transcriptional up-regulation of
proinflammatory markers, for example, E-selectin and VCAM-1,
is known to be regulated by the nuclear factor B (NF-B)
signaling pathway.18,24 We analyzed the activation of the NF-B
pathway by detection of p65 (subunit of NF-B) in the nucleus of
endothelial cells (Figure 1C-D). Stimulation of endothelial cells
with tumor necrosis factor- (TNF) is known to induce nuclear
localization of p65, and this activation was used as a positive
control.18 Inflammatory-like activation of HMVECs was deter-
mined by p65 localization in the nucleus and could be confirmed
only in coculture with LS-180 cells, leukocytes, and platelets.
Cell-cell interactions are responsible for the activation of
microvascular endothelial cells
Tumor cell interactions with platelets and leukocytes (PMNs and
monocytes) can be mediated by selectins.9,13,21,25 Furthermore,
selectin-mediated interactions facilitate cell activation.26 Because
the coculture of LS180 cells with leukocytes but without platelets
did not induce E-selectin expression in HMVECs (Figure 2A), we
hypothesized that P-selectin–mediated interactions of platelets
with tumor cells are responsible for the observed activation of
endothelial cells. Upon addition of a function-blocking P-selectin
antibody to the coculture, minimal activation of endothelial cells
could be detected (Figure 2B). To further confirm the role of
selectins in the initiation of endothelial activation, we removed the
selectin ligands on LS180 and Colo205 cells by treating with
O-sialoglycoproteinase prior to coculturing on HMVECs with
PMNs, monocytes, and platelets. Removal of carcinoma mucins by
O-sialoglycoproteinase treatment led to a significant reduction of
endothelial activation (Figure 2C). Finally, we analyzed HT-29 and
Caco-2 tumor cells that are lacking ligands for L- and P-selectins.25
Whereas a coculture with only HT-29 or Caco-2 cells did not
induce E-selectin expression on HMVECs, coincubation of these
tumor cells together with leukocytes and platelets led to a minimal
enhancement of E-selectin expression and no activation of the
NF-B pathway (Figure 2D-E). These findings indicate that
selectin-mediated cell-cell interactions within the microenviron-
ment of tumor cells mediate the activation of the endothelium.
Figure 1. Interactions of tumor cells with platelets
and leukocytes activate HMVECs. (A) Human lung
microvascular endothelial cells (HMVECs) were cocul-
tured with LS180 or Colo205 cells in the absence or
presence of polymorphonuclear leukocytes (PMNs),
monocytes, and platelets. Representative flow cytomet-
ric data of E-selectin expression on HMVECs are shown.
CD105 was used to identify HMVECs. (B) Statistical
analysis of multiple coculture experiments (n  4-6)
measuring E-selectin expression on HMVECs. Percent-
age of E-selectin–positive HMVECs is presented (mean
 SEM). Statistical significance was determined by Bon-
ferroni multiple comparison test. **P 	 .01; ***P 	 .001.
(C) Representative fluorescence images of p65 localiza-
tion in HMVECs. Nuclear localization of p65 was deter-
mined by colocalization (white) of p65 (red) with DAPI
(4,6 diamidino-2-phenylindole [Sigma]; blue. HMVECs
were detected by CD31 antibody (green). (D) Relative
nuclear localization of p65 in HMVECs determined by
Imaris software. Data are presented as mean  SEM of
3 independent experiments.
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Activated endothelial cells express genes associated with
metastasis
To characterize the endothelial response within a metastatic
microenvironment, we analyzed the transcriptome of cocultured
HMVECs using oligonucleotide microarrays (data deposited in
GEO public database under the accession number GSE1811322).
The comparison of HMVECs cocultured with tumor cells and
blood elements (platelets, PMNs, and monocytes) with HMVECs
cocultured only with blood elements led to the identification of
several genes previously associated with cancer progression and
metastasis (Figure 3A-B). Among others, an enhanced expression
of matrix metalloproteinases MMP1 and MMP10 was detected
(Figure 3B). These proteinases were previously shown to influence
the primary tumor growth as well as the colonization of lungs.27,28
CCL5, a known inflammatory chemokine (also known as
RANTES), was among the most highly induced genes (Figure 3B).
The enhanced expression of identified genes was validated by
quantitative RT-PCR analysis (supplemental Figure 3). CCL5 was
previously shown to be implicated in the promotion of breast
cancer metastasis.29 Detection of CCL5 was also found to be
associated with cancer progression of different other carcino-
mas.30-32 We detected a more than 5-fold increase in CCL5
expression by HMVECs cocultured with LS180, leukocytes, and
platelets for 8 hours compared with HMVECs cocultured with only
leukocytes, and platelets. CCL5 was not detected in HMVECs
alone or in HMVECs cocultured with only LS180 cells and was
minimally induced upon incubation with platelets and leukocytes
only (Figure 3B). Enhanced E-selectin expression detected by
microarrays (supplemental Figure 4) confirmed the initial flow
cytometric analysis (Figure 1, supplemental Figure 2).
By contrast, coculturing HMVECs with HT-29 cells, leukocytes, and
platelets induced an entirely different expression profile than with
LS180 cells (Figure 3A and supplemental Figure 5). These results were
in agreement with previously observed differences in the endothelial
cell activation (Figures 1A, 2D). Accordingly, CCL5 expression of
HMVECs was only minimally induced in a coculture of HT-29 cells
with blood elements (supplemental Figure 3). These results indicate that
HT-29 and LS180 use different means to interact with their metastatic
microenvironment. However, one gene in particular, the regulator of
G-protein signaling 4 (RGS-4), was found to be strongly down-
regulated in HMVECs cocultured with both tumor cell lines in the
presence of blood elements. RGS-4 is an inhibitor of G-protein signaling
and was identified among down-regulated genes in endothelial cells
during angiogenesis.33 RGS-4 expression in HMVECs was slightly
reduced when cocultured with leukocytes and platelets alone, but was
practically absent in cocultures with LS180 or HT-29 cells (supplemen-
tal Figure 3).
Microvascular endothelial cells respond specifically to
interactions with tumor cells
Endothelial cells are phenotypically heterogeneous depending on
their location in the vascular tree.34 Interactions of tumor cells with
the endothelium during metastatic colonization occur primarily on
a microvascular level.1,27 Thus, we aimed to compare the inter-
actions of tumor cells with microvascular endothelial cells
(HMVECs) and macrovascular endothelial cells (human umbilical
vein endothelial cells [HUVECs]). In contrast to HMVECs,
coculture of HUVECs with tumor cells and blood elements resulted
in minimal enhancement of E-selectin expression (supplemental
Figure 4). Microarray analysis of purified HMVECs and HUVECs
from cocultures with LS180 cells and blood elements yielded more
than 1000 genes, which were more than 2-fold differently ex-
pressed (P 	 .05). Specific induction of CCL5 and versican was
observed in HMVECs, whereas it was absent in HUVECs (Figure
Figure 2. Selectin ligands on tumor cells mediate the
inflammatory response of HMVECs. (A) E-selectin ex-
pression by quiescent HMVECs (left) and by HMVECs
cocultured with LS180, PMNs, and monocytes (right).
(B) E-selectin expression on HMVECs after the coculture
with blood elements and LS180 or Colo205 cells in the
presence of a P-selectin function-blocking antibody
(10 g/mL). (C) E-selectin expression on HMVECs cocul-
tured with blood elements and LS180 or Colo205
cells, treated with O-sialoglycoproteinase (OSGPase) or
sham treated. Mean  SEM. **P 	 .01 by 2-tailed Stu-
dent t test. (D) Representative flow cytometric data of
E-selectin expression on HMVECs cocultured with HT-29
or Caco-2 cells either in the absence or presence of
blood elements (PMNs, monocytes, and platelets).
(E) Relative nuclear translocation of p65 in HMVECs
cocultured with HT-29 cells, leukocytes, and platelets.
Stimulation with TNF- was used as a positive control of
endothelial activation. Mean  SEM of 3 independent
experiments.
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3C and supplemental Figure 3). Versican interactions with CD44
contribute to the retention of inflammatory cells.35 CCL5 and other
chemokines are known to bind versican, which thereby modulates
the chemotaxis of leukocytes.35 Our findings demonstrate that
microvascular endothelial cells are more responsive to tumor
cell–induced stimulation than macrovascular endothelial cells.
Microvascular CCL5 expression is stimulated by tumor cells,
PMNs, and platelets
Due to the known association of CCL5 with cancer progression,29,30,36
we further evaluated the functionality of CCL5 expression by
HMVECs. CCL5 is chemotactic for different subtypes of leukocytes
that have been involved in cancer progression including myeloid cells
such as monocytes.37 Thus, we tested the possibility that interactions of
tumor cells with PMNs and platelets can stimulate the expression of
CCL5 in the microvasculature leading to the recruitment of monocytes.
HMVECs were cocultured with platelets, PMNs, and LS180 or
Colo205 cells, followed by detection of CCL5 (Figure 4A-B). Signifi-
cant production of CCL5 was detected both on transcript and protein
level. Again, the removal of selectin ligands from tumor cells by
O-sialoglycoproteinase treatment significantly reduced secretion of
CCL5 by HMVECs (supplemental Figure 6). To ensure that the secreted
CCL5 originated from activated HMVECs, adherent cells were exten-
sively washed after coculture and the production of CCL5 was
determined in freshly added medium. Thus, we excluded the contribu-
tion of platelet-derived CCL5. Tumor cells (LS180 and HT-29) do not
express any CCL5.38 Monocyte adherence to and migration toward
HMVECs that were previously cocultured with PMNs, platelets, and
LS180 cells were increased (Figure 4C-D and supplemental Figure 7),
thereby suggesting that the interactions of tumor cells with platelets and
PMNs are sufficient for the endothelial activation. Stimulation of
HMVECs with TNF- and interferon 
 proved that CCL5 expression
can be induced in HMVECs by inflammatory cytokines, and the
amounts of CCL5 are relevant for the recruitment of monocytes.
Furthermore, the migration of monocytes could be blocked by the
addition of an anti-CCL5 antibody (Figure 4D). Similarly, Met-
RANTES, a CCR1 and CCR5 receptor antagonist,23,39 led to inhibition
of monocyte migration (supplemental Figure 7). Hence, we conclude
that selectin-dependent cell-cell interactions between tumor cells, PMNs,
and platelets stimulate functional CCL5 secretion by microvascular
endothelial cells.
CCL5 is expressed in the metastatic microenvironment and
mediates monocyte recruitment
Results from in vitro experiments provided evidence for the involve-
ment of platelets and leukocytes in tumor cell–induced activation of
endothelial cells and CCL5 expression. To determine whether enhanced
CCL5 expression contributes to metastasis we analyzed the presence of
CCL5 within the microenvironment of metastasizing tumor cells in
vivo. We used MC-38GFP colon carcinoma cell line originated from a
C57Bl/6J mouse background that was previously shown to metastasize
in P- and L-selectin–dependent manner.13,14 C57Bl/6J mice were
intravenously injected with MC-38GFP tumor cells and killed at various
time points. Lung sections were analyzed for the presence of CCL5 in
the vicinity of arrested tumor cells either by immunostaining (Figure
5A-B) or by in situ hybridization (supplemental Figure 8). Although
most of the CCL5 signal was associated with CD31 endothelial cells
(Figure 5A), some staining was associated with nonendothelial cells.
Figure 3. Coculture of endothelial cells with tumor cells and blood
elements induces expression of inflammation-associated genes in-
cluding CCL5. (A) Expression map (red indicates strong expression;
green, no expression) of genes that were significantly differentially ex-
pressed (P 	 .05, ANOVA, Benjamini-Hochberg posthoc test) in HMVECs
cocultured as indicated. (B) Expression map of the highest up-regulated
endothelial transcripts in HMVECs cocultured with blood elements and
LS180 cells (plat, leukos, LS180) compared with HMVECs cocultured
only with leukocytes and platelets (plat, leukos). Mean expression of
3 independent experiments is presented by the indicated color code
(P 	 .05 by 2-tailed Student t test). (C) Fold changes of genes that were
strongly induced in HMVECs cocultured with blood elements and LS180
cells compared with human umbilical vein endothelial cells (HUVECs)
cocultured in the same condition. Genes that were differentially expressed
between quiescent HMVECs and quiescent HUVECs were previously
subtracted from the list (P 	 .05 by 2-tailed Student t test).
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CCL5 is a secreted, relatively small protein that is not stored within the
cell, therefore not all of the CCL5 signal is necessarily associated with
the secreting cell.40 Moreover, previous findings showed that CCL5 was
detected in pulmonary stromal fibroblasts of human lung adenocarci-
noma specimens.36 Thus, activated interstitial fibroblast could be
Figure 4. Endothelial CCL5 expression. (A) Detection of C-C chemokine ligand 5
(CCL5) mRNA in HMVECs purified from cocultures as indicated. Mean  SEM;
n  3. As positive controls, HMVECs were stimulated with TNF (10 ng/mL) and
interferon 
 (1 ng/mL). (B) CCL5 protein levels secreted by cocultured HMVECs and
measured by cytometric bead array. The de novo CCL5 production was measured in
the newly added medium after 12 hours. Mean  SEM; n  6-8. (C) Adherence of
monocytes to HMVECs activated by different coculture conditions. Monocytes were
allowed to adhere to HMVEC layers for 2 hours. Mean  SEM; n  4. (D) Migration
of monocytes toward cocultured HMVECs. Migration of monocytes was determined
in the presence of a CCL5-blocking antibody or of a corresponding isotype control
IgG. Mean  SEM; 3 independent experiments. Statistical significance was deter-
mined ANOVA with Bonferonni multiple comparison test; *P 	 .05, **P 	 .01,
***P 	 .001.
Figure 5. CCL5 recruits monocytes to the metastatic microenvironment.
(A) Representative immunofluorescence images of CCL5 detection (red) in lung
sections from mice injected with MC-38GFP cells (green). Endothelial cells were
stained with CD31 antibody (gray) and nuclei by DAPI (blue). CCL5 expression
colocalized with endothelial cells (left side of the 12-hour image). Bar represents
20 m. (B) Quantification of CCL5 signal in a defined area around MC-38GFP tumor
cells (15 000 m3). CCL5 detection was significantly higher at 12 hours compared
with 6 hours and 48 hours after tumor cell injection (**P 	 .01; *P 	 .05), tested by
ANOVA and Bonferroni posthoc test. (C) Representative images of lung sections
from mice treated with Met-RANTES, injected with MC-38GFP cells (green), and
killed 48 hours later. Monocytes were detected with F4/80 antibody (red) and nuclei
by DAPI (blue). Magnification 40/0.75 NA oil objective. Bar represents 100 m.
Insets show tumor cell microenvironment at higher magnification (63/1.30 NA oil
objective). (D) Quantification of tumor-associated F4/80-positive cells. Statistical
analysis of Met-RANTES– and PBS-treated mice (n  3); ***P 	 .001.
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another source of CCL5 in this experimental metastasis model. CCL5
was also reported to be present in platelets and T cells.41,42 In our
experiment CCL5 was detected around tumor foci between 12 and
24 hours after tumor cell injection. In the experimental metastasis
model, however, platelets are nearly absent after 12 hours in the
microenvironment of metastasizing MC-38GFP cells (supplemental
Figure 9).14 Furthermore, a reduced CCL5 expression around the tumor
foci was observed in mice injected with a P-selectin function-blocking
antibody, further supporting the vital role of platelets during the
initiation phase of metastasis (supplemental Figure 9). In addition, no
association of CD2 T cells and NK cells was observed at 12 and
24 hours after the injection of MC-38GFP cells (data not shown). Thus,
it is unlikely that platelets or T cells significantly contribute to the
increased expression of CCL5 during metastatic colonization. Previ-
ously we reported an L-selectin–dependent recruitment of monocytes
and PMNs to metastasizing tumor cells in the same time period,
between 12 and 24 hours after tumor cell injection.14 The temporal and
spatial nature of endothelial CCL5 expression led us to consider CCL5
as a factor responsible for the recruitment of monocytes. To test this
hypothesis, we determined the presence of monocytes within the tumor
cell microenvironment. Indeed, we found the number of F4/80-positive
cells to be significantly reduced upon Met-RANTES treatment (Figure
5C-D), thus providing evidence for the function of CCL5 by recruitment
of monocytes. At the same time Met-RANTES treatment had no effect
on the number of F4/80-positive cells in the lungs, which were not
associated with tumor cells (data not shown). The current data suggest
that tumor cells, with PMNs and platelets, initiate the activation of
endothelium (Figure 4, supplemental Figure 9) and thereby facilitate the
creation of a permissive metastatic microenvironment reflected in
expression of chemokines (such as CCL5), subsequently mediating the
recruitment of monocytes.
Inhibition of monocyte recruitment confines lung colonization
To precisely monitor the effect of Met-RANTES on the initiation steps
of metastasis following the entry of tumor cells into the bloodstream we
used an experimental metastasis model. When we analyzed mouse lungs
48 hours after tumor cell injection (at the end of Met-RANTES
treatment), a significant reduction of surviving tumor cells could be
observed (Figure 6A). However, the initial seeding of tumor cells in the
lungs was unaffected by the Met-RANTES treatment (data not shown).
Previously, we showed that the survival of MC-38GFP cells decreased
with the reduction of tumor-associated CD11b cells, indicating a
positive correlation between leukocyte recruitment and metastasis.14
Treatment of mice with Met-RANTES during the first 48 hours after
injection of MC-38GFP cells attenuated metastasis as observed 3 weeks
later (Figure 6B). We further analyzed human colon carcinoma cells,
LS180 and HT-29 cells, which showed a different capacity to induce
Figure 6. CCL5 enhances metastasis of murine and
human tumor cells. (A) Survival of MC-38GFP cells in
lungs of mice treated with Met-RANTES and killed
48 hours after tumor cell injection (n  3). (B) Met-
RANTES attenuates metastasis of MC-38GFP cells.
Mice were treated with Met-RANTES for 48 hours after
tumor cell injection and killed 3 weeks later. The extent of
metastasis was determined by GFP measurement.
(C) Metastasis of LS180 human tumor cells in athymic
mice treated with Met-RANTES for 48 hours after tumor
cell injection and killed 5 weeks later. Histologic evalua-
tion of mouse lungs from mice injected with LS180 cells
for the presence of tumor nodules. (D) Metastasis of
LS180 and HT-29 tumor cells in mouse lungs was
determined by quantitative RT-PCR analysis of human
EpCAM expression and normalized to murine GAPDH
levels. **P 	 .01, ***P 	 .001 by 2-tailed Student t test;
ns indicates not significant. (E) Representative images of
hematoxylin-eosin–stained lung sections from mice in-
jected with LS180 cells. Bar represents 100 m.
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CCL5 expression of endothelial cells in vitro (Figure 4). Metastasis was
determined by performing quantitative RT-PCR analysis of human
EpCAM transcripts and counting the metastatic nodules (Figure 6C-E).
Met-RANTES treatment during the first 48 hours after the intravenous
injection of tumor cells in immune-deficient mice attenuated metastasis
of LS180 cells (Figure 6C-E). In contrast, minimal metastasis of HT-29
cells was observed regardless of Met-RANTES treatment (Figure 6D).
These observations indicate that the difference between LS180 cells and
HT-29 cells lies in their capability to activate endothelium through
selectin-mediated interactions and this defines their metastatic behavior.
Moreover, CCR1 and CCR5, the main receptors for CCL5, were
expressed on neither MC-38GFP nor LS180 tumor cells, excluding the
direct effect of CCL5 signaling on tumor cells via its receptors (supplemen-
tal Figure 10). Taken together these data provide evidence that the
endothelial CCL5 expression within the microenvironment of metastasiz-
ing tumor cells enhances tissue colonization.
Discussion
In this work we provide evidence that cellular interactions of tumor cells
with leukocytes and platelets activate microvascular endothelial cells.
Endothelial activation was previously described to promote metastasis
in different experimental models.4,15,16 Tumor cells, metastasizing to the
liver, induced TNF secretion by Kupffer cells that subsequently
activated endothelial cells.15 Inhibition of this activation strongly
reduced liver colonization. Reduction of endothelial activation in the
pulmonary microvasculature of p38/ heterozygous mice was associ-
ated with decreased lung colonization.16 Here we show that cell-cell
interactions leading to pulmonary endothelial activation are, at least in
part, P- and L-selectin dependent, although the presence of platelets was
essential for this process. This finding is further supported by earlier
experiments where the absence of P-selectin and L-selectin–mediated
interactions either in selectin-deficient mice or by the removal of mucins
by O-sialoglycoproteinase led to an attenuation of metastasis.9,13,14,43
Moreover, the complex interactions among tumor cells, leukocytes, and
platelets induced a specific expression profile in microvascular endothe-
lial cells, characterized by the up-regulation of several molecules
previously associated with metastasis including CCL5.
The contribution of platelets and leukocytes together with tumor
cells to endothelial activation was thoroughly analyzed in vitro (Figures
1-3). Data show that recruitment of platelets together with PMNs is
required for endothelial activation and CCL5 expression. Furthermore,
enhanced CCL5 expression was biologically active as determined by
recruitment of monocytes (Figure 4). In a mouse model, the local
expression of CCL5 was detected in the tumor microenvironment
(Figure 5A-B). We could show that the recruitment of platelets is
essential for the enhanced presence of CCL5 that correlated in a timely
manner with the recruitment of monocyte-derived macrophages, F4/80
cells (Figure 5C-D). Whether the initial recruitment of leukocytes to
tumor cells is dependent solely on CCL5 expression induced by
selectin-mediated interactions observed in vitro or CCL5 expression is
rather a consequence of local activation resulting in monocyte recruit-
ment observed in vivo remains to be determined. Further analysis of
initial events during metastasis indicates that the recruitment of mono-
cytes is preceded by the presence of platelets and PMNs, thus further
supporting the timely character of events during this process (L.B.,
manuscript in preparation).
Chemokines and their receptors were shown to contribute to
cancer progression either by directly affecting tumor cells or by
modulating the tumor stroma.32,44 Expression of CXC chemokine
receptor 4 or CCR7 on breast cancer cells was shown to direct
metastasis to the lung or lymph nodes.45 Here we provide evidence
that the expression of CCL5 within the metastatic microenviron-
ment contributes to tissue colonization by tumor cells. CCL5 was
previously associated with the progression of breast cancer in
several independent studies, but only a direct effect on tumor cells
was examined.29,30,36,46,47 Accordingly, CCL5 derived from mesen-
chymal stem cells was found to induce a metastatic phenotype
through binding to its receptor CCR5 on tumor cells within the
primary tumor that increased metastasis to the lungs.29 In our
model we observed a CCL5-dependent recruitment of monocytes
to metastasizing tumor cells, suggesting a function of CCL5 in
shaping the metastatic microenvironment rather than directly
affecting tumor cells (supplemental Figure 11). Although platelet-
derived CCL5 may additionally promote this process, the absence of
platelets at the time of CCL5 detection in the experimental lung metastasis
model suggests only a supporting role in this context (supplemental Figure
9). Thus, the local expression of CCL5 likely enhances lung colonization
by recruiting innate immune cells to the metastatic microenvironment.
This finding was further validated using Met-RANTES in 2 different
metastasis models. Met-RANTES treatment during the first 48 hours after
tumor cell injection strongly decreased lung colonization by MC-38GFP
and LS180 tumor cells. In a previous study, Met-RANTES was success-
fully tested as an inhibitor of primary tumor growth in a xenograft model
and was also linked to the reduction of monocytes in the tumor stroma.37
Innate immune cells are known to promote cancer progression by
inducing immune suppression, and promoting angiogenesis and inva-
sion.11,12 Furthermore, the recruitment of immune cells to the metastatic
niche before or during initiation of metastasis was found to be important
for the successful organ colonization and cancer progression.48-51 In this
context, CCL5-mediated activation of monocytes stimulates production
of CCL2 and MMP9 that can additionally contribute to the recruitment of
inflammatory cells and support the survival of tumor cells.44 We show
here a potential mechanism for how CCL5 facilitates spreading of the
disease by contributing to the formation of a permissive metastatic
microenvironment via the recruitment of innate immune cells, monocytes.
Further studies are needed to clarify whether and how CCL5 contributes
to local tumor invasion.
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